Reimagining ADCs To Beat Cancer
We're hunting for the missing link in ADC development.
The Challenge
Antibody-Drug Conjugates (ADCs) are the future of precision oncology, but 90% of patients still face treatment limiting adverse effects, and many cancers lack approved ADCs due to insufficient efficacy.
The Mission
Deliver the next generation of high efficacy, low side-effect ADCs for hard to-treat-cancers, by using the SIFTR platform to drive high throughput ADC linker development.
Why New Linkers?
The linker is the central component of an ADC and is essential for accurate tumour targeting. However, they’re often neglected in R&D.
93% of approved ADCs use linkers developed over 20 years ago.
Siftr is moving beyond this outdated technology, unlocking new possible treatments for cancer.
Our Approach
Computational, cellular, and even animal models can’t fully account for the complexities of human biology and the wide variability in how cancer manifests across patients. Instead, we’re using human patient tumour tissue to design our linkers.
Scientific Advisory Board
We are Backed by:
Siftr receives investment of £1 million to deliver improved ADCs
A new Imperial spinout aims to improve the performance of an emerging class of cancer treatments known as antibody-drug conjugates or ADCs.
Siftr receives investment of £1 million to deliver improved ADCs
A new Imperial spinout aims to improve the performance of an emerging class of cancer treatments known as antibody-drug conjugates or ADCs.
Chemical & Engineering News highlights Siftr's plans
Spin-out from Ed Tate’s lab focuses on improving conjugate chemistry in the popular anticancer modality
Chemical & Engineering News highlights Siftr's plans
Spin-out from Ed Tate’s lab focuses on improving conjugate chemistry in the popular anticancer modality
Siftr platform wins £827K grant for Prof. Tate's Imperial lab
A grant from the Engineering and Physical Sciences Research Council (EPSRC) will support research into antibody-drug conjugate (ADC) linker technology
Siftr platform wins £827K grant for Prof. Tate's Imperial lab
A grant from the Engineering and Physical Sciences Research Council (EPSRC) will support research into antibody-drug conjugate (ADC) linker technology
Siftr awarded £70K by prestigious Cancer Tech Accelerator
Cancer Tech Accelerator, the entrepreneur training programme from Capital Enterprise dedicated to supporting cutting-edge oncology technology commercialisation, has announced that six teams from its 2024 cohort have been accepted onto Phase II of the accelerator.
Siftr awarded £70K by prestigious Cancer Tech Accelerator
Cancer Tech Accelerator, the entrepreneur training programme from Capital Enterprise dedicated to supporting cutting-edge oncology technology commercialisation, has announced that six teams from its 2024 cohort have been accepted onto Phase II of the accelerator.
